18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.
January 2008 in “Projeto: revista mensal de arquitetura” This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.
September 2002 in “Oncology Times” This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
3 citations
,
October 2024 in “Cancers” In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.
